CliffBio
small molecule

SYFOVRE

PEGCETACOPLAN

Loss of exclusivityDecember 2038latest FDA-listed patent expiry
CompanyApellis Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameSYFOVRE
Active ingredientPEGCETACOPLAN
Strength15MG/0.1ML (15MG/0.1ML)
Dosage formSOLUTION
RouteINTRAVITREAL
ModalitySmall molecule
FDA approvalFebruary 2023
Marketing statusRX

Listed patents

PatentExpiresType
12458695December 2038product
11903994February 2037use U-3828
12528836October 2036use U-4394
10875893November 2033substance
10035822November 2033substance
11292815November 2033substance, product
10125171August 2033substance
11661441January 2033substance
7989589December 2027substance
7888323December 2027substance
9169307November 2027substance
8168584April 2027use U-3542
9056076October 2026use U-3540

Regulatory exclusivity

CodeExpires
NCEMay 2026
NPFebruary 2026

More from Apellis Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SYFOVRE patent cliff — loss of exclusivity December 2038 | CliffBio